CMS’ New Payment Rule Offers a Small Rate Increase but Bigger Financial Challenges
CMS proposes a 2.4% increase in outpatient payment rates for 2027. The agency calculated the update using a projected 3.2% hospital market basket increase, offset by a 0.8 percentage-point productivity adjustment. Ambulatory Surgical Centers (ASCs) that meet the same quality requirements would receive the same payment update.
However, the payment increase represents only one part of the proposal. Several additional policy changes could significantly reduce reimbursement for many hospitals, creating broader financial pressure despite the headline rate increase.
340B Payment Cuts Become the Biggest Shift in the CMS Payment Rule
One of the most significant changes targets hospitals participating in the 340B Drug Pricing Program. CMS proposes replacing the current reimbursement methodology, which pays hospitals the acquisition cost plus 6%, with a payment rate equal to 33.4% below hospitals’ reported acquisition costs.
According to CMS, the proposal would reduce Medicare spending while lowering beneficiary costs. The agency estimates Medicare patients would save approximately $1.15 billion, and taxpayers would save another $4.55 billion. At the same time, the proposal could substantially reduce hospital revenue from outpatient drug reimbursement, potentially influencing purchasing strategies and investment priorities across healthcare organizations.
CMS Expands Site-Neutral Payments, Adding New Pressure on Hospital Imaging Services
CMS also plans to expand its site-neutral payment policy beyond drug administration services. Under the proposal, many imaging procedures performed in off-campus hospital outpatient departments, including most non-contrast MRI services, would receive reimbursement based on the physician fee schedule rather than the hospital outpatient payment system.
CMS estimates this change would generate roughly $260 million in savings during 2027, including reductions in Medicare Part B spending, beneficiary premiums, and patient cost-sharing. Nevertheless, hospitals argue that the lower reimbursement could further reduce operating margins for outpatient services.
Why the CMS Payment Rule Could Influence Drug Purchasing Beyond Hospital Budgets
The proposal also continues CMS’ long-term effort to move additional procedures from the inpatient-only list to outpatient settings. Approximately half of the remaining inpatient-only procedures would become eligible for outpatient reimbursement, while cardiovascular procedures are expected to transition beginning in 2028.
Although these measures primarily target Medicare payment policy, they could also influence hospital investment decisions, service expansion, purchasing priorities, and pharmaceutical procurement strategies. As financial pressure grows, healthcare providers may reassess spending across clinical operations, capital investments, and drug purchasing, creating broader effects throughout the pharmaceutical supply chain.
Hospital Leaders Warn the CMS Payment Rule Could Push Many Providers Into Financial Strain
Healthcare organizations responded critically to the proposal, arguing that the combination of reduced 340B reimbursement and broader site-neutral payment policies would outweigh the 2.4% payment increase for many providers.
Industry representatives stated that hospitals already face rising operational costs, increasing numbers of uninsured patients, and growing demand for complex care. They argue that additional reimbursement reductions could weaken financial stability and limit access to comprehensive healthcare services.
As CMS opens the proposal for public review, the final rule will likely receive significant attention from hospitals, pharmaceutical stakeholders, and healthcare policy experts because its financial impact could extend well beyond reimbursement rates and influence broader healthcare spending throughout 2027.
Organizations facing growing financial and regulatory pressure need quality systems that support smarter decisions, stronger compliance, and sustainable operational performance. Explore Zamann Pharma’s Quality Management System services to learn how we help pharmaceutical teams build resilient, inspection-ready quality systems for long-term success.
Source: Medcitynews.Com